Larry Biegelsen Quotes

Although the strategic rationale for combining Boston Scientific and Guidant appears compelling, we have lingering concerns.

- Larry Biegelsen

Tags

Strategic | Rationale | Combining | Boston | Scientific |

comments powered by Disqus

Random

Don't count BSX out yet. We expect BSX to continue to pursue GDT by potentially modifying or increasing its $72/share offer. - Larry Biegelsen

We believe that Boston Scientific can raise its offer to $78 a share and still maintain an investment-grade credit rating. - Larry Biegelsen

In our view, Abbott is the clear winner in this deal. - Larry Biegelsen